Report cover image

FIC Single-target Drugs Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 138 Pages
SKU # APRC20261478

Description

Summary

According to APO Research, the global FIC Single-target Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for FIC Single-target Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for FIC Single-target Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for FIC Single-target Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of FIC Single-target Drugs include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Polarean lmaging and Phathom, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for FIC Single-target Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding FIC Single-target Drugs.

The report will help the FIC Single-target Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.



The FIC Single-target Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global FIC Single-target Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

FIC Single-target Drugs Segment by Company

Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Polarean lmaging
Phathom
Marinus
Mallinckrodt
ImmunoGen
Immunocore
Gilead
Genentech
Dermavant Sciences
Boehringer Ingelheim
BMS
Agios
FIC Single-target Drugs Segment by Type

ALK2 Inhibitors
Citron Inhibitors
GCN2 Agonists
RORγ Covalent Inhibitors
Others
FIC Single-target Drugs Segment by Application

Hospital
Clinic
Other
FIC Single-target Drugs Segment by Region


North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Single-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of FIC Single-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Single-target Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of FIC Single-target Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of FIC Single-target Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of FIC Single-target Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

138 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global FIC Single-target Drugs Market Size (2020-2031)
2.2.2 Global FIC Single-target Drugs Sales (2020-2031)
2.2.3 Global FIC Single-target Drugs Market Average Price (2020-2031)
2.3 FIC Single-target Drugs by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 ALK2 Inhibitors
2.3.3 Citron Inhibitors
2.3.4 GCN2 Agonists
2.3.5 RORγ Covalent Inhibitors
2.3.6 Others
2.4 FIC Single-target Drugs by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Clinic
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global FIC Single-target Drugs Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global FIC Single-target Drugs Sales (K Units) of Manufacturers (2020-2025)
3.3 Global FIC Single-target Drugs Revenue of Manufacturers (2020-2025)
3.4 Global FIC Single-target Drugs Average Price by Manufacturers (2020-2025)
3.5 Global FIC Single-target Drugs Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of FIC Single-target Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of FIC Single-target Drugs, Product Type & Application
3.8 Global Manufacturers of FIC Single-target Drugs, Established Date
3.9 Global FIC Single-target Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Sanofi
4.1.1 Sanofi Company Information
4.1.2 Sanofi Business Overview
4.1.3 Sanofi FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Sanofi FIC Single-target Drugs Product Portfolio
4.1.5 Sanofi Recent Developments
4.2 Johnson & Johnson
4.2.1 Johnson & Johnson Company Information
4.2.2 Johnson & Johnson Business Overview
4.2.3 Johnson & Johnson FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Johnson & Johnson FIC Single-target Drugs Product Portfolio
4.2.5 Johnson & Johnson Recent Developments
4.3 Novartis
4.3.1 Novartis Company Information
4.3.2 Novartis Business Overview
4.3.3 Novartis FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Novartis FIC Single-target Drugs Product Portfolio
4.3.5 Novartis Recent Developments
4.4 Merck
4.4.1 Merck Company Information
4.4.2 Merck Business Overview
4.4.3 Merck FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Merck FIC Single-target Drugs Product Portfolio
4.4.5 Merck Recent Developments
4.5 Roche
4.5.1 Roche Company Information
4.5.2 Roche Business Overview
4.5.3 Roche FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Roche FIC Single-target Drugs Product Portfolio
4.5.5 Roche Recent Developments
4.6 Eli Lilly
4.6.1 Eli Lilly Company Information
4.6.2 Eli Lilly Business Overview
4.6.3 Eli Lilly FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Eli Lilly FIC Single-target Drugs Product Portfolio
4.6.5 Eli Lilly Recent Developments
4.7 Pfizer
4.7.1 Pfizer Company Information
4.7.2 Pfizer Business Overview
4.7.3 Pfizer FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Pfizer FIC Single-target Drugs Product Portfolio
4.7.5 Pfizer Recent Developments
4.8 Polarean lmaging
4.8.1 Polarean lmaging Company Information
4.8.2 Polarean lmaging Business Overview
4.8.3 Polarean lmaging FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Polarean lmaging FIC Single-target Drugs Product Portfolio
4.8.5 Polarean lmaging Recent Developments
4.9 Phathom
4.9.1 Phathom Company Information
4.9.2 Phathom Business Overview
4.9.3 Phathom FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Phathom FIC Single-target Drugs Product Portfolio
4.9.5 Phathom Recent Developments
4.10 Marinus
4.10.1 Marinus Company Information
4.10.2 Marinus Business Overview
4.10.3 Marinus FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Marinus FIC Single-target Drugs Product Portfolio
4.10.5 Marinus Recent Developments
4.11 Mallinckrodt
4.11.1 Mallinckrodt Company Information
4.11.2 Mallinckrodt Business Overview
4.11.3 Mallinckrodt FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Mallinckrodt FIC Single-target Drugs Product Portfolio
4.11.5 Mallinckrodt Recent Developments
4.12 ImmunoGen
4.12.1 ImmunoGen Company Information
4.12.2 ImmunoGen Business Overview
4.12.3 ImmunoGen FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.12.4 ImmunoGen FIC Single-target Drugs Product Portfolio
4.12.5 ImmunoGen Recent Developments
4.13 Immunocore
4.13.1 Immunocore Company Information
4.13.2 Immunocore Business Overview
4.13.3 Immunocore FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Immunocore FIC Single-target Drugs Product Portfolio
4.13.5 Immunocore Recent Developments
4.14 Gilead
4.14.1 Gilead Company Information
4.14.2 Gilead Business Overview
4.14.3 Gilead FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Gilead FIC Single-target Drugs Product Portfolio
4.14.5 Gilead Recent Developments
4.15 Genentech
4.15.1 Genentech Company Information
4.15.2 Genentech Business Overview
4.15.3 Genentech FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Genentech FIC Single-target Drugs Product Portfolio
4.15.5 Genentech Recent Developments
4.16 Dermavant Sciences
4.16.1 Dermavant Sciences Company Information
4.16.2 Dermavant Sciences Business Overview
4.16.3 Dermavant Sciences FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Dermavant Sciences FIC Single-target Drugs Product Portfolio
4.16.5 Dermavant Sciences Recent Developments
4.17 Boehringer Ingelheim
4.17.1 Boehringer Ingelheim Company Information
4.17.2 Boehringer Ingelheim Business Overview
4.17.3 Boehringer Ingelheim FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.17.4 Boehringer Ingelheim FIC Single-target Drugs Product Portfolio
4.17.5 Boehringer Ingelheim Recent Developments
4.18 BMS
4.18.1 BMS Company Information
4.18.2 BMS Business Overview
4.18.3 BMS FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.18.4 BMS FIC Single-target Drugs Product Portfolio
4.18.5 BMS Recent Developments
4.19 Agios
4.19.1 Agios Company Information
4.19.2 Agios Business Overview
4.19.3 Agios FIC Single-target Drugs Sales, Revenue and Gross Margin (2020-2025)
4.19.4 Agios FIC Single-target Drugs Product Portfolio
4.19.5 Agios Recent Developments
5 Global FIC Single-target Drugs Market Scenario by Region
5.1 Global FIC Single-target Drugs Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global FIC Single-target Drugs Sales by Region: 2020-2031
5.2.1 Global FIC Single-target Drugs Sales by Region: 2020-2025
5.2.2 Global FIC Single-target Drugs Sales by Region: 2026-2031
5.3 Global FIC Single-target Drugs Revenue by Region: 2020-2031
5.3.1 Global FIC Single-target Drugs Revenue by Region: 2020-2025
5.3.2 Global FIC Single-target Drugs Revenue by Region: 2026-2031
5.4 North America FIC Single-target Drugs Market Facts & Figures by Country
5.4.1 North America FIC Single-target Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America FIC Single-target Drugs Sales by Country (2020-2031)
5.4.3 North America FIC Single-target Drugs Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe FIC Single-target Drugs Market Facts & Figures by Country
5.5.1 Europe FIC Single-target Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe FIC Single-target Drugs Sales by Country (2020-2031)
5.5.3 Europe FIC Single-target Drugs Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific FIC Single-target Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific FIC Single-target Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific FIC Single-target Drugs Sales by Country (2020-2031)
5.6.3 Asia Pacific FIC Single-target Drugs Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America FIC Single-target Drugs Market Facts & Figures by Country
5.7.1 South America FIC Single-target Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America FIC Single-target Drugs Sales by Country (2020-2031)
5.7.3 South America FIC Single-target Drugs Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa FIC Single-target Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa FIC Single-target Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa FIC Single-target Drugs Sales by Country (2020-2031)
5.8.3 Middle East and Africa FIC Single-target Drugs Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global FIC Single-target Drugs Sales by Type (2020-2031)
6.1.1 Global FIC Single-target Drugs Sales by Type (2020-2031) & (K Units)
6.1.2 Global FIC Single-target Drugs Sales Market Share by Type (2020-2031)
6.2 Global FIC Single-target Drugs Revenue by Type (2020-2031)
6.2.1 Global FIC Single-target Drugs Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global FIC Single-target Drugs Revenue Market Share by Type (2020-2031)
6.3 Global FIC Single-target Drugs Price by Type (2020-2031)
7 Segment by Application
7.1 Global FIC Single-target Drugs Sales by Application (2020-2031)
7.1.1 Global FIC Single-target Drugs Sales by Application (2020-2031) & (K Units)
7.1.2 Global FIC Single-target Drugs Sales Market Share by Application (2020-2031)
7.2 Global FIC Single-target Drugs Revenue by Application (2020-2031)
7.2.1 Global FIC Single-target Drugs Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global FIC Single-target Drugs Revenue Market Share by Application (2020-2031)
7.3 Global FIC Single-target Drugs Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 FIC Single-target Drugs Value Chain Analysis
8.1.1 FIC Single-target Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 FIC Single-target Drugs Production Mode & Process
8.2 FIC Single-target Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 FIC Single-target Drugs Distributors
8.2.3 FIC Single-target Drugs Customers
9 Global FIC Single-target Drugs Analyzing Market Dynamics
9.1 FIC Single-target Drugs Industry Trends
9.2 FIC Single-target Drugs Industry Drivers
9.3 FIC Single-target Drugs Industry Opportunities and Challenges
9.4 FIC Single-target Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.